Abderrahim Fandi

6.1k total citations · 2 hit papers
50 papers, 4.4k citations indexed

About

Abderrahim Fandi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Abderrahim Fandi has authored 50 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 10 papers in Otorhinolaryngology. Recurrent topics in Abderrahim Fandi's work include Lung Cancer Treatments and Mutations (20 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Research Studies (10 papers). Abderrahim Fandi is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Research Studies (10 papers). Abderrahim Fandi collaborates with scholars based in United States, France and Italy. Abderrahim Fandi's co-authors include Giorgio V. Scagliotti, Michael Wolf, Roy S. Herbst, Giuseppe Giaccone, Steven D. Averbuch, Christian Manegold, David H. Johnson, Judith Ochs, Rafael Rosell and Ronald B. Natale and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Abderrahim Fandi

48 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

2004 1.4k citations Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology profile →
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

2004 1.4k citations Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Abderrahim Fandi United States	20	3.2k	3.0k	1.1k	552	525	50	4.4k
Frank Dunphy United States	25	2.4k 0.7×	2.1k 0.7×	735 0.7×	476 0.9×	334 0.6×	65	3.6k
Neal Ready United States	36	4.2k 1.3×	2.8k 0.9×	1.1k 1.0×	481 0.9×	466 0.9×	160	5.7k
Vincenzo Adamo Italy	27	2.4k 0.7×	2.2k 0.7×	1.0k 0.9×	699 1.3×	367 0.7×	118	3.8k
Erminia Massarelli United States	32	3.2k 1.0×	2.1k 0.7×	1.2k 1.2×	648 1.2×	510 1.0×	140	4.6k
Thomas Gauler Germany	30	1.6k 0.5×	1.7k 0.6×	797 0.7×	481 0.9×	547 1.0×	152	3.1k
Francisco Robert United States	28	1.8k 0.6×	1.4k 0.5×	1.1k 1.0×	312 0.6×	231 0.4×	107	3.2k
Jin Hyoung Kang South Korea	28	1.7k 0.5×	1.9k 0.6×	1.0k 0.9×	679 1.2×	472 0.9×	116	3.1k
Michael Millward Australia	25	1.7k 0.5×	1.1k 0.4×	1.1k 1.1×	331 0.6×	331 0.6×	43	2.9k
M. Mueser France	10	3.8k 1.2×	1.9k 0.6×	795 0.7×	464 0.8×	682 1.3×	18	4.5k
V.A. Miller United States	22	2.1k 0.7×	1.6k 0.5×	924 0.9×	508 0.9×	323 0.6×	83	3.0k

Countries citing papers authored by Abderrahim Fandi

Since Specialization

Citations

This map shows the geographic impact of Abderrahim Fandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abderrahim Fandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abderrahim Fandi more than expected).

Fields of papers citing papers by Abderrahim Fandi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abderrahim Fandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abderrahim Fandi. The network helps show where Abderrahim Fandi may publish in the future.

Co-authorship network of co-authors of Abderrahim Fandi

This figure shows the co-authorship network connecting the top 25 collaborators of Abderrahim Fandi. A scholar is included among the top collaborators of Abderrahim Fandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abderrahim Fandi. Abderrahim Fandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Rohlff, Christian, et al.. (2022). 1374 Characterization and validation of a humanized lead antibody against OX003, a novel immuno-oncology target. Regular and Young Investigator Award Abstracts. A1428–A1428. 1 indexed citations

2.

Levy, Benjamin, Giuseppe Giaccone, Benjamin Besse, et al.. (2019). Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer. 108. 120–128. 48 indexed citations

3.

Cortés, Javier, José Manuel Pérez-García, Yin Wan, et al.. (2018). Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. Clinical Breast Cancer. 18(5). e919–e926. 9 indexed citations

4.

Vogelzang, Nicholas J., Karim Fizazi, John M. Burke, et al.. (2016). Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. European Urology. 71(2). 168–171. 45 indexed citations

5.

Mesı́a, Ricard, Paolo Bossi, Aaron R. Hansen, et al.. (2016). Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. Journal of Clinical Oncology. 34(15_suppl). 6029–6029.

6.

Sonpavde, Guru, Gregory R. Pond, Arnoud J. Templeton, et al.. (2015). Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. European Urology. 69(6). 980–983. 14 indexed citations

7.

Rini, Brian I., Bruce G. Redman, J. Garcia, et al.. (2014). A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Annals of Oncology. 25(9). 1794–1799. 9 indexed citations

8.

Ellis, Peter, et al.. (2013). A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(4). 423–428. 8 indexed citations

9.

Giaccone, Giuseppe, Renee Iacona, Abderrahim Fandi, et al.. (2008). Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal of Cancer Research and Clinical Oncology. 135(3). 467–476. 9 indexed citations

10.

Pujol, Jean-Louis, et al.. (2006). Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 1(5). 417–424. 19 indexed citations

11.

Pujol, Jean-Louis, et al.. (2006). Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 1(5). 417–424. 14 indexed citations

12.

Manegold, Christian, et al.. (2005). A Pilot Trial of Gefitinib in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 6(6). 343–349. 16 indexed citations

13.

Giaccone, Giuseppe, J.L. González-Larriba, A.T. van Oosterom, et al.. (2004). Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Annals of Oncology. 15(5). 831–838. 52 indexed citations

14.

Giaccone, Giuseppe, Roy S. Herbst, Christian Manegold, et al.. (2004). Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. Journal of Clinical Oncology. 22(5). 777–784. 1388 indexed citations breakdown →

15.

Massarelli, Erminia, Fabrice André, D. D. Liu, et al.. (2002). A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 39(1). 55–61. 163 indexed citations

16.

Hasbini, Ali, Abderrahim Fandi, Nadia Chouaki, et al.. (1999). Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype. Annals of Oncology. 10(4). 421–425. 42 indexed citations

17.

Ducreux, Michel, Philippe Rougier, Abderrahim Fandi, et al.. (1998). Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Annals of Oncology. 9(6). 653–656. 138 indexed citations

18.

Fandi, Abderrahim, A. Taamma, N. Azli, et al.. (1997). Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type. Head & Neck. 19(1). 41–47. 15 indexed citations

19.

Altun, Musa, Abderrahim Fandi, Olivier Dupuis, et al.. (1995). Undifferentiated nasopharyngeal cancer (UCNT): Current diagnostic and therapeutic aspects. International Journal of Radiation Oncology*Biology*Physics. 32(3). 859–877. 131 indexed citations

20.

Fandi, Abderrahim, et al.. (1994). Nasopharyngeal cancer: epidemiology, staging, and treatment.. PubMed. 21(3). 382–97. 168 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact